EXELIXIS INC (EXEL) Stock News

Don't overlook NASDAQ:EXEL—a stock with solid growth prospects and a reasonable valuation.

NASDAQ:EXEL is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced.

NASDAQ:EXEL: good value for what you're paying.

EXELIXIS INC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:EXEL showcases decent financial health and profitability, coupled with an attractive price.

Why Exelixis Stock Trounced the Market on Thursday

Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?

Exelixis reaffirmed its 2025 sales guidance of $2.15-$2.25 billion and reported sustained long-term efficacy for Cabometyx in advanced renal cell carcinoma.

Mentions: BMY PFE

Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program

Top 5 Biotech Stocks That Got Most Retail Buzz Last Week

From merger updates to earnings surprises, these healthcare stocks saw the biggest spike in Stocktwits chatter.

Mentions: GLYC GRAL ADMA MBRX

Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025

Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit

A Glimpse Into The Expert Outlook On Exelixis Through 21 Analysts

Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update

2 Stocks to Buy With Less Than $40

Mentions: VKTX

Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025

BeiGene Stock Meets 80-Plus RS Rating Benchmark

One key metric to look for in a stock is an 80-plus Relative Strength Rating. BeiGene stock just hit that mark, with a jump to 84 Wednesday.

Mentions: ONC CPRX HALO

BridgeBio Pharma Stock Earns 87 RS Rating

BridgeBio Pharma stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 64 to 87.

Mentions: BBIO CPRX HALO

SpringWorks Therapeutics Stock Sees RS Rating Jump To 86

On Monday, SpringWorks Therapeutics stock hit a key technical milestone, seeing its Relative Strength Rating jump to 86.

Mentions: SWTX CPRX ADMA

Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025

Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Mentions: MRNA ALNY CORT ADMA ...

SpringWorks Therapeutics Stock Gets A RS Rating Lift

The Relative Strength (RS) Rating for SpringWorks Therapeutics stock entered a higher percentile Wednesday, as it got a lift from 62 to 76.

Mentions: SWTX ADMA HALO

Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025

Arcellx Stock Earns 82 Relative Strength Rating

Arcellx stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 79 to 82.

Mentions: ACLX CPRX ADMA